Jefferies Group LLC Nektar Therapeutics Call Options Transaction History

Jefferies Group LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Sep 21, 2023	SELL	$3.17 - $6.17 $194,955 - $379,455	-61,500 Reduced 70.13%	26,200 $99,000
Q2 2022 Aug 15, 2022	SELL	$3.17 - $6.17 $194,955 - $379,455	-61,500 Reduced 70.13%	26,200 $100,000
Q1 2022 Sep 21, 2023	BUY	$4.16 - $13.72 $364,832 - $1.2 Million	87,700 New	87,700 $472,000
Q1 2022 May 16, 2022	BUY	$4.16 - $13.72 $206,336 - $680,512	49,600 Added 130.18%	87,700 $473,000
Q4 2018 Feb 14, 2019	BUY	$30.43 - $56.65 $304,300 - $566,500	10,000 Added 35.59%	38,100 $1.25 Million
Q3 2018 Nov 14, 2018	BUY	$46.46 - $68.49 $552,874 - $815,030	11,900 Added 73.46%	28,100 $1.71 Million
Q2 2018 Aug 14, 2018	BUY	$46.25 - $104.45 $749,250 - $1.69 Million	16,200 New	16,200 $791,000

146

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $197M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.